Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Matsuo, Teppei ^a   Nishizuka, Satoshi S ^a   Ishida, Kazushige ^a   Iwaya, Takeshi ^a   Ikeda, Miyuki ^a   Wakabayashi, Go ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955745530     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-140     Document Type: Article

References (28)

1. Review of epidermal growth factor receptor biology. RS Herbst, Int J Radiat Oncol Biol Phys 2004 59 2 Suppl 21 6 15142631 (Pubitemid 38610223)
2. The epidermal growth factor receptor ligands at a glance. MR Schneider E Wolf, J Cell Physiol 2009 218 3 460 6 10.1002/jcp.21635 19006176
3. Interaction of antibodies with ErbB receptor extracellular regions. KR Schmitz KM Ferguson, Exp Cell Res 2009 315 4 659 70 10.1016/j.yexcr.2008.10.008 18992239
4. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. NI Goldstein, et al. Clin Cancer Res 1995 1 11 1311 8 9815926
5. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. SK Blick LJ Scott, Drugs 2007 67 17 2585 607 10.2165/00003495-200767170-00008 18034592 (Pubitemid 350159168)
6. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. E Van Cutsem, et al. N Engl J Med 2009 360 14 1408 17 10.1056/NEJMoa0805019 19339720
7. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. W Roock De, et al. Lancet Oncol 2010 11 8 753 62 10.1016/S1470-2045(10)70130-3 20619739
8. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. P Laurent-Puig, et al. J Clin Oncol 2009 27 35 5924 30 10.1200/JCO.2008.21.6796 19884556
9. Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. J Tie, et al. Int J Cancer 2010
10. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF (V600E) mutation. J Tie, et al. Int J Cancer 2011 128 9 2075 84 10.1002/ijc.25555 20635392
11. Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. Y Nakanishi, et al. BMC Cancer 2011 11 3 10.1186/1471-2407-11-3 21205319
12. Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. VA Levin, et al. J Proteome Res 2010 9 1 179 91 10.1021/pr900392b 19894763
13. Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. M Keese, et al. J Biol Chem 2005 280 30 27826 31 10.1074/jbc.M504485200 15908435 (Pubitemid 41076898)
14. An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells. HS Liu, et al. Carcinogenesis 2010 31 8 1456 64 10.1093/carcin/bgq100 20498137
15. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. YD Jung, et al. Br J Cancer 2001 84 6 844 50 10.1054/bjoc.2000.1691 11259102 (Pubitemid 32275661)
16. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. YD Jung, et al. Cancer Res 1999 59 19 4804 7 10519388 (Pubitemid 29472880)
17. Mitogen-activated protein kinase signaling in drug-resistant neuroblastoma cells. RR Mattingly, Methods Mol Biol 2003 218 71 83 12616713
18. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. S Nishizuka, et al. Proc Natl Acad Sci USA 2003 100 24 14229 34 10.1073/pnas.2331323100 14623978 (Pubitemid 37499219)
19. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. D Atkins, et al. J Histochem Cytochem 2004 52 7 893 901 10.1369/jhc.3A6195.2004 15208356 (Pubitemid 38857154)
20. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. A Licar P Cerkovnik S Novakovic, Med Oncol 2010
21. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. H Rajagopalan, et al. Nature 2002 418 6901 934 10.1038/418934a 12198537 (Pubitemid 34976022)
22. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. YF Hsu, et al. Mol Cancer 2010 9 139 10.1186/1476-4598-9-139 20529262
23. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. T Yoshida, et al. Int J Cancer 2008 122 7 1530 8 18033688 (Pubitemid 351294961)
24. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Z Fan, et al. J Biol Chem 1994 269 44 27595 602 7961676 (Pubitemid 24346592)
25. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. S Li, et al. Cancer Cell 2005 7 4 301 11 10.1016/j.ccr.2005.03.003 15837620 (Pubitemid 40544648)
26. Signal transduction and endocytosis: close encounters of many kinds. A Sorkin M Von Zastrow, Nat Rev Mol Cell Biol 2002 3 8 600 14 10.1038/nrm883 12154371
27. Internalization of the epidermal growth factor receptor: role in signalling. A Sorkin, Biochem Soc Trans 2001 29 Pt 4 480 4 11498013 (Pubitemid 32783642)
28. Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction. Y Suzuki, et al. Virchows Arch 1994 424 5 453 7 8032525 (Pubitemid 24213601)